236 related articles for article (PubMed ID: 28819279)
21. Analysis of the MTHFR (methylenetetrahydrofolate reductase) 677 C>T and 1298 A>C polymorphisms in BCR-ABL-negative myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Popp RA; Costache RM; Coadă CA; Sarca AD; Urian LG; Dima D; Petrov L; Farcaş MF; Militaru MS; Pop IV
Int J Lab Hematol; 2013 Feb; 35(1):e9-12. PubMed ID: 23107469
[No Abstract] [Full Text] [Related]
22. Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis.
Vener C; Novembrino C; Catena FB; Fracchiolla NS; Gianelli U; Savi F; Radaelli F; Fermo E; Cortelezzi A; Lonati S; Menegatti M; Deliliers GL
Exp Hematol; 2010 Nov; 38(11):1058-65. PubMed ID: 20655352
[TBL] [Abstract][Full Text] [Related]
23. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.
Skov V; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC; Larsen TS
Exp Hematol; 2012 Sep; 40(9):771-780.e19. PubMed ID: 22659388
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative disorders and myelofibrosis.
Zimmerman MP; Mehr SR
Am J Manag Care; 2012 May; 18(3 Spec No.):SP131-3. PubMed ID: 22642280
[No Abstract] [Full Text] [Related]
26. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Masarova L; Alhuraiji A; Bose P; Daver N; Pemmaraju N; Cortes J; Pierce S; Kantarjian H; Verstovsek S
Eur J Haematol; 2018 Mar; 100(3):257-263. PubMed ID: 29226426
[TBL] [Abstract][Full Text] [Related]
27. ASXL1 mutations in primary and secondary myelofibrosis.
Ricci C; Spinelli O; Salmoiraghi S; Finazzi G; Carobbio A; Rambaldi A
Br J Haematol; 2012 Feb; 156(3):404-7. PubMed ID: 21923651
[No Abstract] [Full Text] [Related]
28. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
29. Prodromal myeloproliferative neoplasms: the 2008 WHO classification.
Kvasnicka HM; Thiele J
Am J Hematol; 2010 Jan; 85(1):62-9. PubMed ID: 19844986
[TBL] [Abstract][Full Text] [Related]
30. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.
Gowin K; Coakley M; Kosiorek H; Mesa R
Haematologica; 2016 Oct; 101(10):e405-e406. PubMed ID: 27354022
[No Abstract] [Full Text] [Related]
31. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.
Gerds AT
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):407-414. PubMed ID: 31808852
[TBL] [Abstract][Full Text] [Related]
32. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Kvasnicka HM; Thiele J
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
[TBL] [Abstract][Full Text] [Related]
33. [Megakaryoblastic transformation in polycythemia vera--a case of megakaryoblastic leukemia associated with myelofibrosis and elevation of serum PDGF-like activity].
Oda K; Katoh O; Kawano M; Iwato K; Kimura A; Imamura N; Fujimura K; Kuramoto A; Yasui W; Kajihara H
Rinsho Ketsueki; 1986 Nov; 27(11):2118-23. PubMed ID: 3820629
[No Abstract] [Full Text] [Related]
34. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.
Mora B; Guglielmelli P; Rumi E; Maffioli M; Barraco D; Rambaldi A; Caramella M; Komrokji RS; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Albano F; Benevolo G; Cavalloni C; Uccella S; Accetta R; Siracusa C; Agnoli S; Merli M; Barbui T; Bertù L; Cazzola M; Vannucchi AM; Passamonti F
Am J Hematol; 2020 Jan; 95(1):E1-E3. PubMed ID: 31588594
[No Abstract] [Full Text] [Related]
35. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).
Chen X; Williams WV; Sandor V; Yeleswaram S
J Clin Pharmacol; 2013 Jul; 53(7):721-30. PubMed ID: 23677817
[TBL] [Abstract][Full Text] [Related]
36. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.
Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Spadea A; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
J Hematol Oncol; 2021 Jul; 14(1):119. PubMed ID: 34325728
[TBL] [Abstract][Full Text] [Related]
37. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Mesa RA; Verstovsek S; Cervantes F; Barosi G; Reilly JT; Dupriez B; Levine R; Le Bousse-Kerdiles MC; Wadleigh M; Campbell PJ; Silver RT; Vannucchi AM; Deeg HJ; Gisslinger H; Thomas D; Odenike O; Solberg LA; Gotlib J; Hexner E; Nimer SD; Kantarjian H; Orazi A; Vardiman JW; Thiele J; Tefferi A;
Leuk Res; 2007 Jun; 31(6):737-40. PubMed ID: 17210175
[TBL] [Abstract][Full Text] [Related]
38. Patho-anatomical features of the bone marrow.
Lennert K; Nagai K; Schwarze EW
Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191
[No Abstract] [Full Text] [Related]
39. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
[No Abstract] [Full Text] [Related]
40. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
Boiocchi L; Vener C; Savi F; Bonoldi E; Moro A; Fracchiolla NS; Iurlo A; Deliliers GL; Coggi G; Bosari S; Gianelli U
J Clin Pathol; 2011 Mar; 64(3):226-31. PubMed ID: 21217153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
